{"id":6996,"date":"2014-10-08T23:00:00","date_gmt":"2014-10-08T23:00:00","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/"},"modified":"2014-10-08T23:00:00","modified_gmt":"2014-10-08T23:00:00","slug":"nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/","title":{"rendered":"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex"},"content":{"rendered":"<div>Sophia Antipolis, France.<\/div>\n<div>\u00a0<\/div>\n<div><strong>Nicox S.A. <\/strong>(NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui d\u2019avoir \u00e9t\u00e9 inform\u00e9e par Aciex Therapeutics, Inc. que l\u2019USPTO am\u00e9ricain (United States Patent and Trademark Office) a d\u00e9livr\u00e9 un brevet am\u00e9ricain (N\u00b0 8 829 005) couvrant AC-170 (Cetirizine Ophthalmic Compositions) et un brevet am\u00e9ricain (N\u00b0 8 765 725) couvrant AC-155 (Fluticasone Propionate Nano-crystalline Compositions).<\/div>\n<div>\u00a0<\/div>\n<div>Avec ces nouveaux brevets, AC-170 et AC-155 seront prot\u00e9g\u00e9s respectivement jusqu\u2019au 15 mars 2030 et jusqu\u2019au 7 janvier 2033. Pour plus d\u2019informations, veuillez consulter le <a href=\"http:\/\/www.businesswire.com\/news\/home\/20141008005210\/en\/Aciex-Therapeutics-Announces-Issuance-Separate-U.S.-Patents#.VDZs1vl_uzM#.VDaj4_JOKM8\">communiqu\u00e9 de presse Aciex du 8 octobre 2014 <\/a>(en anglais).<\/div>\n<div>\u00a0<\/div>\n<div>Aciex Therapeutics, Inc. est une soci\u00e9t\u00e9 pharmaceutique am\u00e9ricaine de d\u00e9veloppement en ophtalmologie, \u00e0 capitaux priv\u00e9s. Aciex dispose d\u2019un portefeuille solide de m\u00e9dicaments \u00e0 un stade de d\u00e9veloppement tr\u00e8s avanc\u00e9 ciblant des segments majeurs du march\u00e9 de l&rsquo;ophtalmologie, y compris l&rsquo;allergie et l&rsquo;inflammation. En juillet 2014, Nicox a conclu un accord en vue d\u2019acqu\u00e9rir 100% du capital d&rsquo;Aciex.<\/div>\n<div>\u00a0<\/div>\n<div>Pour plus d\u2019informations, veuillez consulter le\u00a0<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/pr2014070200fr2.pdf\">communiqu\u00e9 de presse Nicox du 2 juillet 2014\u00a0<\/a>et le \u00ab\u00a0<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/1-amber-document-e-avec-n-enregistrement1.pdf\">Document E<\/a>\u00a0\u00bb enregistr\u00e9 aupr\u00e8s de l\u2019AMF le 30 septembre 2014 sous le num\u00e9ro E.14-060\u00a0(disponible sur le site Internet de Nicox\u00a0www.nicox.com, rubrique Espace Investisseurs \/ Assembl\u00e9es G\u00e9n\u00e9rales).<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France. \u00a0 Nicox S.A. (NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui d\u2019avoir \u00e9t\u00e9 inform\u00e9e par Aciex Therapeutics, Inc. que l\u2019USPTO am\u00e9ricain (United States Patent and Trademark Office) a d\u00e9livr\u00e9 un brevet am\u00e9ricain (N\u00b0 8 829 005) couvrant AC-170 (Cetirizine Ophthalmic Compositions) et un brevet am\u00e9ricain (N\u00b0 8 765 [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6996","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France. \u00a0 Nicox S.A. (NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui d\u2019avoir \u00e9t\u00e9 inform\u00e9e par Aciex Therapeutics, Inc. que l\u2019USPTO am\u00e9ricain (United States Patent and Trademark Office) a d\u00e9livr\u00e9 un brevet am\u00e9ricain (N\u00b0 8 829 005) couvrant AC-170 (Cetirizine Ophthalmic Compositions) et un brevet am\u00e9ricain (N\u00b0 8 765 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2014-10-08T23:00:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex\",\"datePublished\":\"2014-10-08T23:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\\\/\"},\"wordCount\":228,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\\\/\",\"name\":\"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2014-10-08T23:00:00+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex - Nicox","og_description":"Sophia Antipolis, France. \u00a0 Nicox S.A. (NYSE Euronext Paris : COX), soci\u00e9t\u00e9 internationale sp\u00e9cialis\u00e9e en ophtalmologie, annonce aujourd\u2019hui d\u2019avoir \u00e9t\u00e9 inform\u00e9e par Aciex Therapeutics, Inc. que l\u2019USPTO am\u00e9ricain (United States Patent and Trademark Office) a d\u00e9livr\u00e9 un brevet am\u00e9ricain (N\u00b0 8 829 005) couvrant AC-170 (Cetirizine Ophthalmic Compositions) et un brevet am\u00e9ricain (N\u00b0 8 765 [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/","og_site_name":"Nicox","article_published_time":"2014-10-08T23:00:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/"},"author":{"name":"","@id":""},"headline":"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex","datePublished":"2014-10-08T23:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/"},"wordCount":228,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/","url":"https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/","name":"Nicox : Information sur la d\u00e9livrance de brevets am\u00e9ricains pour Aciex - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2014-10-08T23:00:00+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-information-sur-la-delivrance-de-brevets-americains-pour-aciex\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6996"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6996\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}